Clinical Trials Results - National Cancer Institute

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -5 of 5 Show results per page	View Search Criteria \| Help With Results

Last Modified: 10/11/2008 First Published: 3/17/2006


1.		Phase I/II Study of Motexafin Gadolinium Given Concurrently With Temozolomide and Fractionated Radiotherapy in Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme or Gliosarcoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				NCI				RTOG-0513 RTOG-0513, NCT00305864

Last Modified: 10/17/2008 First Published: 10/6/2006


2.		Phase II Study of Motexafin Gadolinium and Involved-Field Radiotherapy in Pediatric Patients With Intrinsic Pontine Glioma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				21 and under at diagnosis				NCI				COG-ACNS0222 ACNS0222, NCT00387790

Last Modified: 5/9/2008 First Published: 8/3/2007


3.		Phase II Study of Concurrent and Adjuvant Temozolomide With Radiotherapy in Young Patients With Diffuse Pontine Gliomas

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Diagnostic, Supportive care, Treatment				Active				2 to 21				Other				CCLG-CNS-2007-04 CNS 2007 04, EU-20746, EUDRACT-2007-001768-60, NCT00514397

First Published: 7/15/2008


4.		Phase II Pilot Study of Neoadjuvant Sunitinib Malate Followed by Cytoreductive Nephrectomy and Adjuvant Sunitinib Malate in Patients With Stage IV Renal Cell Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Diagnostic, Treatment				Active				18 and over				NCI, Pharmaceutical / Industry				UPCC-10807 UPCC 10807, PFIZER-807184, NCT00717587

First Published: 8/12/2008


5.		Phase II Pilot Study of Motexafin Gadolinium Combined With High-Dose Methotrexate-Based Chemotherapy, Rituximab, and Whole-Brain Radiotherapy in Patients With Newly Diagnosed Primary Central Nervous System Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Approved-not yet active				Over 18				NCI, Pharmaceutical / Industry				NU-05H7 NU 05H7, PCI-P-NU-05H7, NCT00734773

Select All on One Page